NeoGenomics Q4 Revenue Up 40 Percent
Test volumes, revenues per test and costs per test improved during the quarter, the company said.
NeoGenomics Q3 Revenues Grow 51 Percent
Clinical services revenues rose 56 percent to $92.6 million while pharma services grew 26 percent to $12.1 million.
Bionano Customers Explore Diagnostic Applications of Genome Maps in Cancer, Genetic Disorders
Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.
NeoGenomics Q4 Revenues Rise 25 Percent Bolstered by Genoptix Acquisition
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
NeoGenomics, Genoptix Deal Highlights Role of Community Oncologists in Advanced Cancer Testing
NeoGenomics estimates that the more than 2,000 community oncologists represent a $2.5 billion testing opportunity. Its CEO called the segment a "strategic priority."
Oct 23, 2018
NeoGenomics to Acquire Genoptix for Cash, Stock
Feb 28, 2018
Rosetta Genomics, Genoptix Sign New Merger Agreement
Feb 23, 2018
Rosetta Genomics, Genoptix Merger Terminated
Dec 15, 2017
Genoptix to Acquire Rosetta Genomics for $10M
Mar 7, 2017
Novartis Completes Sale of Genoptix Lab Business
Jan 24, 2011